Single Ascending and Multiple Ascending Dose Study of LCA-0061

This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).

NCT Number	NCT07701954
Lead Sponsor	Lycia Therapeutics, Inc.
Conditions	Atopic Disease, Peanut Allergies
Enrollment	72 participants
Start Date	2026-06-26
Primary Completion	2028-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-14